Biotest Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Michael Ramroth

Chief executive officer

€2.7m

Total compensation

CEO salary percentage	20.4%
CEO tenure	18.4yrs
CEO ownership	n/a
Management average tenure	6.9yrs
Board average tenure	less than a year

Recent management updates

Recent updates

CEO Compensation Analysis

How has Michael Ramroth's remuneration changed compared to Biotest's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2022	n/a	n/a	-€54m
Dec 31 2021	€3m	€555k	-€63m
Sep 30 2021	n/a	n/a	-€28m
Jun 30 2021	n/a	n/a	-€33m
Mar 31 2021	n/a	n/a	-€35m
Dec 31 2020	€2m	€462k	-€31m
Sep 30 2020	n/a	n/a	-€34m
Jun 30 2020	n/a	n/a	-€24m
Mar 31 2020	n/a	n/a	-€15m
Dec 31 2019	€1m	€426k	-€5m
Sep 30 2019	n/a	n/a	-€9m
Jun 30 2019	n/a	n/a	-€3m
Mar 31 2019	n/a	n/a	-€6m
Dec 31 2018	€1m	€355k	-€13m
Sep 30 2018	n/a	n/a	€18m
Jun 30 2018	n/a	n/a	€6m
Mar 31 2018	n/a	n/a	€500k
Dec 31 2017	€1m	€355k	-€16m
Sep 30 2017	n/a	n/a	-€48m
Jun 30 2017	n/a	n/a	-€47m
Mar 31 2017	n/a	n/a	-€29m
Dec 31 2016	€1m	€355k	€6m
Sep 30 2016	n/a	n/a	€128m
Jun 30 2016	n/a	n/a	€52m
Mar 31 2016	n/a	n/a	€36m
Dec 31 2015	€1m	€325k	€27m

Compensation vs Market: Michael's total compensation ($USD2.80M) is above average for companies of similar size in the UK market ($USD1.98M).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Ramroth (60 yo)

18.4yrs

Tenure

€2,724,000

Compensation

Dr. Michael Ramroth serves as Chairman of the Management Board and CEO at Biotest Aktiengesellschaft since May 01, 2019. Dr. Ramroth serves as Chief Financial Officer at Biotest Aktiengesellschaft. He serv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Ramroth	Chairman of the Management Board	18.4yrs	€2.72m	no data
Georg Floß	COO & Member of the Board of Management	9.5yrs	€1.73m	no data
Jorg Schuttrumpf	Chief Scientific Officer & Member of the Management Board	less than a year	no data	no data
Monika Buttkereit	Head of Investor Relations	no data	no data	no data
Christina Erb	Head of Corporate HR	6.9yrs	no data	no data
Katrin Bernöster	Head of the Project Management Organisation	no data	no data	no data
Peter Seith	Head of Quality Operations	no data	no data	no data
Dirk Schuck	Member of Supervisory Board	less than a year	no data	no data

6.9yrs

Average Tenure

48yo

Average Age

Experienced Management: 0N6Z's management team is seasoned and experienced (6.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Dirk Schuck	Member of Supervisory Board	less than a year	no data	no data
Xiaoying Gao	Member of Supervisory Board	2.2yrs	€40.00k	no data
Uta Kemmerich-Keil	Member of Supervisory Board	less than a year	no data	no data
Bernhard R. Ehmer	Chairman of the Supervisory Board	less than a year	€598.00k	no data
David Bell	Member of Supervisory Board	less than a year	no data	no data
Jurgen Heilmann	Member of Supervisory Board	10.8yrs	€44.00k	no data
Tomas Gelabert	Deputy Chairman of the Supervisory Board	less than a year	no data	no data

0.2yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 0N6Z's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.

Biotest Management

Management criteria checks 1/4

Key information

Recent management updates

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest AG Announces Board Changes

Recent updates

Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024

Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024

Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with Trimodulin

Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin Yimmugo

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023

Biotest AG Conducts Clinical Phase III Study PreCyssion with Cmv Hyperimmunoglobulin (Cytotect CP Biotest-) for the Prevention of CMV Infection in the Unborn Child in Germany

Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Deficiency

Biotest AG Announces Board Changes

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Biotest Submits Marketing Authorisation Application for IgG Next Generation

Biotest AG Announces Biotest Treats First CMV-Positive Pregnant Woman in Phase III Clinical Trial to Prevent Transmission of CMV Infection to the Unborn Child

Biotest AG Accelerates Trimodulin Development in Hospitalized Covid-19 Patients with Federal Funding from the German Ministries of Health, and Education & Research

Biotest Receives Approval for Phase III Clinical Trial in Pregnant Women for Prevention of CMV Infection of the Unborn Baby

Biotest Announces the Outcome for Its ESsCOVID (Escape from Severe COVID-19) Trial in Patients with Severe COVID-19

Biotest AG Provides Earnings Guidance for the Year 2021

Biotest AG Successfully Completes Recruitment for Its Clinical Trial with Trimodulin in Severe Covid-19 Patients

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age